

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Reh

RRID:CVCL_1650

Type: Cell Line

Proper Citation

RRID:CVCL_1650

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1650

Proper Citation: RRID:CVCL_1650

Description: Cell line Reh is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Childhood B acute lymphoblastic leukemia

Defining Citation: [PMID:194778](#), [PMID:197411](#), [PMID:279400](#), [PMID:2140233](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3866637](#), [PMID:3874327](#), [PMID:7630190](#), [PMID:7888679](#), [PMID:8704231](#), [PMID:8847894](#), [PMID:9067587](#), [PMID:9108419](#), [PMID:9510473](#), [PMID:9680106](#), [PMID:9823951](#), [PMID:10490826](#), [PMID:10739008](#), [PMID:11226526](#), [PMID:14504097](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:16523483](#), [PMID:20164919](#), [PMID:20575032](#), [PMID:21552520](#), [PMID:22460905](#), [PMID:24056532](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27397505](#), [PMID:27922598](#), [PMID:28196595](#), [PMID:28569787](#), [PMID:29786757](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31305009](#), [PMID:31978347](#), [PMID:35124168](#), [PMID:35354797](#), [PMID:35839778](#)

Comments: Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Reh

Synonyms: REH

Cross References: BTO:BTO_0001163, CLO:CLO_0008781, CLO:CLO_0008782, EFO:EFO_0022409, CLDB:cl4132, AddexBio:C0003031/4985, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-8286, BCRJ:0321, BioGRID_ORCS_Cell_line:1761, BioSample:SAMN03471040, BioSample:SAMN03473380, BioSample:SAMN10988185, cancercellines:CVCL_1650, CCRID:3101HUMTCHu131, Cell_Model_Passport:SIDM00447, ChEMBL-Cells:ChEMBL3308823, ChEMBL-Targets:ChEMBL2366320, CLS:300320, Cosmic:798668, Cosmic:801720, Cosmic:909696, Cosmic:919149, Cosmic:991551, Cosmic:994183, Cosmic:996287, Cosmic:998706, Cosmic:999751, Cosmic:1012114, Cosmic:1037725, Cosmic:1067440, Cosmic:1093790, Cosmic:1118468, Cosmic:1130244, Cosmic:1191700, Cosmic:1483360, Cosmic:1524815, Cosmic:2491075, Cosmic:2523595, Cosmic:2649233, Cosmic-CLP:909696, DepMap:ACH-000960, DSMZ:ACC-22, DSMZCellDive:ACC-22, EGA:EGAS00001000978, GDSC:909696, GEO:GSM236802, GEO:GSM236838, GEO:GSM482492, GEO:GSM499514, GEO:GSM499538, GEO:GSM499727, GEO:GSM499733, GEO:GSM887530, GEO:GSM888612, GEO:GSM931330, GEO:GSM931331, GEO:GSM1195448, GEO:GSM1374847, GEO:GSM1670369, GEO:GSM2373798, GEO:GSM2373799, GEO:GSM5137740, GEO:GSM5137741, GEO:GSM7701448, GEO:GSM7701449, IARC_TP53:21284, IARC_TP53:28432, LiGeA:CCLE_618, LINCS_LDP:LCL-1039, Lonza:58, PharmacDB:REH_1299_2019, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL_1650, PubChem_Cell_line:CVCL_1650, Wikidata:Q29958043

ID: CVCL_1650

Record Creation Time: 20220427T221455+0000

Record Last Update: 20260913T005853+0000

Ratings and Alerts

No rating or validation information has been found for Reh.

No alerts have been found for Reh.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 36 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Awasthi BP, et al. (2026) Disruption of Cytoskeleton Induces Physiologically and Morphologically Dysfunctional Mitochondria in B-ALL Cells. Cell biochemistry and function,

44(3), e70190.

Zhu JM, et al. (2026) Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models. *EBioMedicine*, 127, 106239.

Wang H, et al. (2026) An immunocompetent bone marrow-on-a-chip model for studying human hematological malignancies and preclinical therapeutic screening. *Nature protocols*.

Garcia C, et al. (2026) FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. *Leukemia*, 40(8), 1763.

Ayad AS, et al. (2026) Chemical Markers and Bioactivity of Algerian Royal Jelly: Influence of Bee Subspecies, Geography, and Lyophilization. *Chemistry & biodiversity*, 23(6), e71406.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Matar S, et al. (2025) Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. *Molecular cancer therapeutics*, 24(6), 816.

Jenkins TW, et al. (2025) Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. *Scientific reports*, 15(1), 17284.

Huang Z, et al. (2025) Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e15472.

Brock L, et al. (2025) KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. *Molecular oncology*, 19(5), 1404.

Mitsuno K, et al. (2025) Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. *Cancer immunology, immunotherapy : CII*, 74(3), 79.

Ma C, et al. (2025) Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. *Nature biomedical engineering*.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. *Research square*.

Konishi H, et al. (2025) Probiotic-derived glucose oxidase exerts therapeutic efficacy against pediatric B-cell acute lymphoblastic leukemia. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 190, 118436.

Hlozkova K, et al. (2024) Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase. *Cancer letters*, 605, 217242.

de Smith AJ, et al. (2024) A noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children. *Cell genomics*, 4(4), 100526.

Piccinini C, et al. (2024) In vitro CAR-T cell killing: validation of the potency assay. *Cancer immunology, immunotherapy : CII*, 73(9), 168.

Chen HC, et al. (2024) Novel immunotherapeutics against LGR5 to target multiple cancer types. *EMBO molecular medicine*, 16(9), 2233.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

González-Novo R, et al. (2023) 3D environment controls H3K4 methylation and the mechanical response of the nucleus in acute lymphoblastic leukemia cells. *European journal of cell biology*, 102(3), 151343.